Cognitive complaints and cognitive impairment in patients with chronic daily headache

Comorbidities in chronic daily headache (CDH) include emotional disorders (depression, anxiety), insomnia, and musculoskeletal pain at other sites. In CDH, the most common type is a subjective  (according to patients themselves) and/or objective (based on the  results of cognitive tests) reduction i...

Full description

Bibliographic Details
Main Authors: V. A. Golovacheva, V. A. Parfenov, A. A. Golovacheva
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2017-12-01
Series:Неврология, нейропсихиатрия, психосоматика
Subjects:
Online Access:https://nnp.ima-press.net/nnp/article/view/796
_version_ 1827062850781184000
author V. A. Golovacheva
V. A. Parfenov
A. A. Golovacheva
author_facet V. A. Golovacheva
V. A. Parfenov
A. A. Golovacheva
author_sort V. A. Golovacheva
collection DOAJ
description Comorbidities in chronic daily headache (CDH) include emotional disorders (depression, anxiety), insomnia, and musculoskeletal pain at other sites. In CDH, the most common type is a subjective  (according to patients themselves) and/or objective (based on the  results of cognitive tests) reduction in cognitive functions, which can  be caused by emotional disorders, insomnia and/or brain diseases,  and a negative effect of chronic pain on cognitive functions.Objective: to analyze cognitive complaints and their changes in patients with CDH.Patients and methods. Subjective complaints and cognitive functions were evaluated in 90 patients (76 women and 14 men) aged 23 to 78 years (mean age, 46.7±12.0 years) with primary  forms of CDH according to the Montreal Cognitive Assessment (MCA) for 12 months. The majority (68.9%) of patients with CHD  complained of diminished memory; however, its mild disorders (25– 26 MCA scores) were found in only a small proportion (23.3%). All  patients with subjective diminished memory were ascertained to  have neurotic disorders (depression, anxiety disorder) and/or insomnia or a concurrence of mental disorder and insomnia.Results and discussion. All the patients received treatment options, including optimal pharmacotherapy for headache and concomitant diseases, an educational conversation, cognitive- behavioral therapy, and therapeutic exercises. In cognitive  impairment (CI), cognitive training was used and Ginkgo biloba  extract (EGb 761®) prescribed; in sleep disorders, sleep hygiene  rules were explained. Therapy declined the mean number of  headache days a month from 29.1±2.03 (at baseline) to 9.3±9.35  (at 12-month follow-up) (p=0.002); while the subjective complaints regressed in the majority of patients; mild MCA changes persisted only in 6.7% of the patients. Management tactics for CHD patients  having mild CI and cardiovascular risk factors and the use of EGb  761® to improve cognitive functions were considered.Conclusion. It has been ascertained that in many cases, CI is associated with emotional disorders and insomnia, as well as with pathophysiological mechanisms of chronic pain itself; CI in some  patients has a vascular origin. The use of combined treatment  programs can promptly and effectively reduce the frequency of  headache and improve cognitive functions. EGb 761® (Tanakan®) has a beneficial effect on subjective CI and mild CI.
first_indexed 2024-04-10T02:02:08Z
format Article
id doaj.art-869a6cee88d3482f9e93b351b32e480b
institution Directory Open Access Journal
issn 2074-2711
2310-1342
language Russian
last_indexed 2025-02-18T20:03:25Z
publishDate 2017-12-01
publisher IMA-PRESS LLC
record_format Article
series Неврология, нейропсихиатрия, психосоматика
spelling doaj.art-869a6cee88d3482f9e93b351b32e480b2024-10-17T16:15:24ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422017-12-0194555910.14412/2074-2711-2017-4-55-59692Cognitive complaints and cognitive impairment in patients with chronic daily headacheV. A. Golovacheva0V. A. Parfenov1A. A. Golovacheva2I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaComorbidities in chronic daily headache (CDH) include emotional disorders (depression, anxiety), insomnia, and musculoskeletal pain at other sites. In CDH, the most common type is a subjective  (according to patients themselves) and/or objective (based on the  results of cognitive tests) reduction in cognitive functions, which can  be caused by emotional disorders, insomnia and/or brain diseases,  and a negative effect of chronic pain on cognitive functions.Objective: to analyze cognitive complaints and their changes in patients with CDH.Patients and methods. Subjective complaints and cognitive functions were evaluated in 90 patients (76 women and 14 men) aged 23 to 78 years (mean age, 46.7±12.0 years) with primary  forms of CDH according to the Montreal Cognitive Assessment (MCA) for 12 months. The majority (68.9%) of patients with CHD  complained of diminished memory; however, its mild disorders (25– 26 MCA scores) were found in only a small proportion (23.3%). All  patients with subjective diminished memory were ascertained to  have neurotic disorders (depression, anxiety disorder) and/or insomnia or a concurrence of mental disorder and insomnia.Results and discussion. All the patients received treatment options, including optimal pharmacotherapy for headache and concomitant diseases, an educational conversation, cognitive- behavioral therapy, and therapeutic exercises. In cognitive  impairment (CI), cognitive training was used and Ginkgo biloba  extract (EGb 761®) prescribed; in sleep disorders, sleep hygiene  rules were explained. Therapy declined the mean number of  headache days a month from 29.1±2.03 (at baseline) to 9.3±9.35  (at 12-month follow-up) (p=0.002); while the subjective complaints regressed in the majority of patients; mild MCA changes persisted only in 6.7% of the patients. Management tactics for CHD patients  having mild CI and cardiovascular risk factors and the use of EGb  761® to improve cognitive functions were considered.Conclusion. It has been ascertained that in many cases, CI is associated with emotional disorders and insomnia, as well as with pathophysiological mechanisms of chronic pain itself; CI in some  patients has a vascular origin. The use of combined treatment  programs can promptly and effectively reduce the frequency of  headache and improve cognitive functions. EGb 761® (Tanakan®) has a beneficial effect on subjective CI and mild CI.https://nnp.ima-press.net/nnp/article/view/796cognitive impairmentsubjective cognitive impairmentmild cognitive impairmentchronic painchronic daily headachetreatmentpreventionginkgo biloba extract (egb 761®).
spellingShingle V. A. Golovacheva
V. A. Parfenov
A. A. Golovacheva
Cognitive complaints and cognitive impairment in patients with chronic daily headache
Неврология, нейропсихиатрия, психосоматика
cognitive impairment
subjective cognitive impairment
mild cognitive impairment
chronic pain
chronic daily headache
treatment
prevention
ginkgo biloba extract (egb 761®).
title Cognitive complaints and cognitive impairment in patients with chronic daily headache
title_full Cognitive complaints and cognitive impairment in patients with chronic daily headache
title_fullStr Cognitive complaints and cognitive impairment in patients with chronic daily headache
title_full_unstemmed Cognitive complaints and cognitive impairment in patients with chronic daily headache
title_short Cognitive complaints and cognitive impairment in patients with chronic daily headache
title_sort cognitive complaints and cognitive impairment in patients with chronic daily headache
topic cognitive impairment
subjective cognitive impairment
mild cognitive impairment
chronic pain
chronic daily headache
treatment
prevention
ginkgo biloba extract (egb 761®).
url https://nnp.ima-press.net/nnp/article/view/796
work_keys_str_mv AT vagolovacheva cognitivecomplaintsandcognitiveimpairmentinpatientswithchronicdailyheadache
AT vaparfenov cognitivecomplaintsandcognitiveimpairmentinpatientswithchronicdailyheadache
AT aagolovacheva cognitivecomplaintsandcognitiveimpairmentinpatientswithchronicdailyheadache